These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36689854)

  • 1. Cost-effectiveness of ceftazidime/avibactam plus metronidazole versus meropenem as first-line empiric therapy for the treatment of complicated intra-abdominal infections: A study based on the in-vitro surveillance data in China.
    Shi X; Fu J; Li X; Lv Q; Wan X; Xu Q
    J Infect Public Health; 2023 Mar; 16(3):361-367. PubMed ID: 36689854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
    Kongnakorn T; Eckmann C; Bassetti M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
    Antimicrob Resist Infect Control; 2019; 8():204. PubMed ID: 31890160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy.
    Tichy E; Torres A; Bassetti M; Kongnakorn T; Di Virgilio R; Irani P; Charbonneau C
    Clin Ther; 2020 May; 42(5):802-817. PubMed ID: 32349879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant
    Varón-Vega FA; Lemos E; Castaño GN; Reyes JM
    Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):235-240. PubMed ID: 34407710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant
    Kong W; Yang X; Shu Y; Li S; Song B; Yang K
    Front Public Health; 2023; 11():1118307. PubMed ID: 36926178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftazidime-avibactam plus metronidazole vs. meropenem in complicated intra-abdominal infections: Indian subset from RECLAIM.
    Rodgers P; Kamat S; Adhav C
    J Infect Dev Ctries; 2022 Feb; 16(2):305-313. PubMed ID: 35298426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the value of new antibiotic treatment strategies in Zhejiang province, China: cost-effectiveness analysis based on a validated dynamic model.
    Yang W; Zhen X; Sun X; Khatiwada SU; Yang D; Chen Y; Dong P; Al-Taie A; Gordon J; Dong H
    BMJ Open; 2024 Aug; 14(8):e086039. PubMed ID: 39209783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia.
    Qin X; Tran BG; Kim MJ; Wang L; Nguyen DA; Chen Q; Song J; Laud PJ; Stone GG; Chow JW
    Int J Antimicrob Agents; 2017 May; 49(5):579-588. PubMed ID: 28363526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections.
    Kongnakorn T; Wagenlehner F; Falcone M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
    Int J Antimicrob Agents; 2019 Nov; 54(5):633-641. PubMed ID: 31202921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.
    Mazuski JE; Gasink LB; Armstrong J; Broadhurst H; Stone GG; Rank D; Llorens L; Newell P; Pachl J
    Clin Infect Dis; 2016 Jun; 62(11):1380-1389. PubMed ID: 26962078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of ceftazidime-avibactam for treatment of carbapenem-resistant
    Simon MS; Sfeir MM; Calfee DP; Satlin MJ
    Antimicrob Agents Chemother; 2019 Sep; 63(12):. PubMed ID: 31548187
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial.
    Lucasti C; Popescu I; Ramesh MK; Lipka J; Sable C
    J Antimicrob Chemother; 2013 May; 68(5):1183-92. PubMed ID: 23391714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial.
    Bradley JS; Broadhurst H; Cheng K; Mendez M; Newell P; Prchlik M; Stone GG; Talley AK; Tawadrous M; Wajsbrot D; Yates K; Zuzova A; Gardner A
    Pediatr Infect Dis J; 2019 Aug; 38(8):816-824. PubMed ID: 31306396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections.
    Chahine EB; Sourial M; Ortiz R
    Consult Pharm; 2015 Dec; 30(12):695-705. PubMed ID: 26671269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
    Prabhu V; Foo J; Ahir H; Sarpong E; Merchant S
    J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.
    Davido B; Crémieux AC; Vaugier I; Gatin L; Noussair L; Massias L; Laurent F; Saleh-Mghir A
    Int J Antimicrob Agents; 2023 Jan; 61(1):106702. PubMed ID: 36476965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftazidime-Avibactam versus Meropenem for the Treatment of Complicated Intra-Abdominal Infections.
    Tan CK; Lai CC; Chao CM
    Antibiotics (Basel); 2019 Dec; 8(4):. PubMed ID: 31817727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
    Kong W; Deng T; Li S; Shu Y; Wu Y
    BMC Infect Dis; 2023 Apr; 23(1):256. PubMed ID: 37085768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program.
    Lin LY; Debabov D; Chang W; Stone G; Riccobene T
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0198521. PubMed ID: 35225651
    [No Abstract]   [Full Text] [Related]  

  • 20. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
    Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
    Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.